Back to Stocks

CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
7 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Charles River Laboratories is demonstrating a decisive operational pivot, transforming its cost structure to thrive despite a cautious biotechnology spending environment.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic operating figures, a deeper look at the financials reveals significant instability.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CRL filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company in the midst of a high-stakes transformation. On one hand, the operational metrics suggest a successful lean-out, with significant margin gains and a strategic pivot away from underperforming assets. On the other hand, the financial results are marred by heavy one-time charges and a worrying contraction in cash flow, indicating that the 'turnaround' is currently being funded by debt and asset sales rather than organic growth. Investors are left to weigh the validity of the 60% operating income jump against the reality of a net loss and rising leverage. The successful vertical integration of the NHP supply chain is a long-term strategic win, but the immediate pressure of a flat backlog and legal contingencies creates a volatile environment. The overall impact of the filing is a shift from a growth-at-all-costs model to a margin-preservation model, though the transition is proving costly and debt-intensive.

Selected Quarter

Core Takeaway

CRL is successfully cutting costs and improving margins, but these gains are currently offset by heavy divestiture losses and a reliance on debt to fund strategic acquisitions.

Investor Lens

The trade-off is between impressive operational efficiency gains and a deteriorating liquidity profile and balance sheet.

Watch Next

The closing of the European Discovery Divestiture and the subsequent impact on the Q2 cash flow statement.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.22Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion
80%
bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss
70%
bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition
60%
neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture
50%
bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback
40%
bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion
80%
bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss
70%
bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition
60%
neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture
50%
bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback
40%
bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion
80%
bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss
70%
bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition
60%
neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture
50%
bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback
40%
bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion
80%
bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss
70%
bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition
60%
neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture
50%
bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback
40%
bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion
80%
bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss
70%
bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition
60%
neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture
50%
bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback
40%
bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion
80%
bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss
70%
bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition
60%
neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture
50%
bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback
40%
bullishMay 7

Operating margins expanded by 440 basis points to 12.0%.

margin expansion
80%
bearishMay 7

Reported a net loss of $14.8 million due to divestiture charges.

earnings miss
70%
bullishMay 7

Acquired Cambodian NHP supplier for $507.3 million to vertically integrate supply chain.

acquisition
60%
neutralMay 7

Sold CDMO and Cell Solutions businesses to GI Partners.

divestiture
50%
bullishMay 7

Repurchased $200 million of common stock during the quarter.

buyback
40%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a company in the midst of a high-stakes transformation. On one hand, the operational metrics suggest a successful lean-out, with significant margin gains and a strategic pivot away from underperforming assets. On the other hand, the financial results are marred by heavy one-time charges and a worrying contraction in cash flow, indicating that the 'turnaround' is currently being funded by debt and asset sales rather than organic growth. Investors are left to weigh the validity of the 60% operating income jump against the reality of a net loss and rising leverage. The successful vertical integration of the NHP supply chain is a long-term strategic win, but the immediate pressure of a flat backlog and legal contingencies creates a volatile environment. The overall impact of the filing is a shift from a growth-at-all-costs model to a margin-preservation model, though the transition is proving costly and debt-intensive.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.